OSE Immunotherapeutics, a biotechnology company focused on the development of innovative immunotherapies for immune activation and regulation in the fields of immuno-oncology and autoimmune diseases

Agenda

19 December 2017
BioMed Event by Invest Securities, Paris

8-10 January 2018
Biotech Showcase, San Francisco

OSE Immunotherapeutics is a biotechnology company dedicated to the development of innovative immunotherapies which act on effector and suppressor cells to stimulate or inhibit the body’s immune response, and to restore immune disorders in the fields of immuno-oncology, autoimmune diseases and transplantation. These new generation products are optimized to better target key receptors of the immune response’s activation or regulation, thus allowing for longer therapeutic effects.

The company has several scientific and technological platforms: neoepitopes, agonist or antagonist monoclonal antibodies, ideally positioned to fight cancer and autoimmune diseases.

Its first-in-class clinical portfolio offers a diversified risk profile.